Orphan Reach was a leading Contract Research Organization (CRO) designed to navigate the complexity of trials in orphan indications. As of the 11th May 2021, Orphan Reach were acquired by Emmes, a global, full-service CRO dedicated to supporting the advancement of public health and biopharmaceutical innovation. Since the acquisition, Orphan Reach has become part of Emmes - functioning as part of Emmes' Rare Disease and Pediatric Center. We are here to accelerate the clinical development of orphan drugs and facilitate patient access to urgently needed new treatments for rare conditions.For our customers – innovative biotech companies – we provide global clinical development services with particular attention to patient recruitment and retention.Our infrastructure allows access to patients with rare diseases in more than 100 countries world-wide. Centrally based Project Management teams in Europe, USA and Asia co-ordinate our task force in each of the local territories and contribute their orphan expertise to accelerate access to new drugs in a wide range of therapeutic areas.Combining Emmes' strategic drug development and advanced statistical capabilities with the exceptional patient- centred global operational experience of Orphan Reach has further extended our leadership in rare and orphan disease research and will ultimately lead to new treatment options for patients.